High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases

Summary

EGFR mutated NSCLC patiens with CNS metastases have poor prognosis. High-dose furmonertinib (160mg/day) have produced high CNS PFS and ORR in second-line for EGFR T790M mutated NSCLC. Whether EGFR mutated NSCLC with CNS metastases can benefit from first-line treatment of high-dose furmonertinib has not been reported. This study aims to investigate the efficacy and safety of high dose furmonertinib in first-line treatment of EGFR mutated NSCLC patiens.

Timeline

Start

2022-05-01

Primary completion

2024-12-31

Completion

2025-03-31

Publications

• Yan H, Jiang W, Xiong Y, Liu L, Zhang R, Ruan Z, Huang Z, Dai J, Tian F, Zhou C, Wang Z, Yang H, Tao W, Zheng H, Xu Q, Yang N, Zeng L, Zhang Y. High-dose furmonertinib as first-line treatment for untreated EGFR-mutated advanced NSCLC with central nervous system metastases: A phase 2 trial. Cell Rep Med. 2026 Jun 30:102904. doi: 10.1016/j.xcrm.2026.102904. Online ahead of print.

Drugs

Indications